Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals filed its Annual Secretarial Compliance Report for FY 2024-25, confirming general compliance with SEBI listing regulations. The company's paid-up share capital crossed the Rs. 10 crore threshold during the year, triggering new regulatory requirements. Two minor non-compliances were noted — a one-day delay in submitting the previous secretarial compliance report (fine of Rs. 2,360, paid in July 2024) and a one-day delay in declaring the record date for dividend (fine of Rs. 11,800, paid in October 2024). The board also received an advisory for not publishing quarterly and yearly financial results in newspapers. Key corporate actions during the year included a stock split (Rs. 10 to Re. 1 per share), a bonus share issue in April 2024, approval received from BSE for a rights issue (terms yet to be announced), and a 10% final dividend declaration.
The compliance lapses were minor with small fines already paid, posing no material risk to shareholders. Shareholders should note the stock split, the bonus shares already issued, the upcoming rights issue (potential dilution to be confirmed), and the 10% final dividend declared. The company appears to be in active restructuring mode, which could affect shareholding patterns.